Dacomitinib (dacomitinib) is a drug developed and produced in which country. Background introduction

Dacomitinib (also known as dacomitinib) is a second-generation oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ( TKI), mainly used to treat EGFR gene mutation-positive non-small cell lung cancer (NSCLC). This drug was developed by the American pharmaceutical company Pfizer (Pfizer) and is one of its important products in the field of targeted treatment of lung cancer. Compared with first-generation EGFR-TKI drugs such as gefitinib and erlotinib, dacomitinib has an irreversible binding effect and has an inhibitory effect on EGFR and its related HER2 and HER4, and its therapeutic breadth has been improved.

Pfizer launched the dacomitinib research and development project in the early 2000s, aiming to develop an improved solution to the problem of resistance to previous EGFR targeted drugs. After years of preclinical research and international multi-center clinical trials, dacomitinib was approved by the US FDA in 2018 for the treatment of metastatic non-small cell lung cancer with EGFR sensitive mutations. Immediately afterwards, Japan, the European Union and other countries and regions also successively approved the marketing of the drug, marking the gradual expansion of its global clinical application.

China's National Medical Products Administration (NMPA) also approved dacomitinib for domestic marketing in 2019, becoming one of the first-line treatment options for domestic EGFR mutated lung cancer patients. The official launch of dacomitinib in the Chinese market means that Chinese patients can enjoy internationally advanced precision targeted therapy drugs earlier. Although this drug is already on the market in China, it is not yet included in medical insurance, and the cost is still borne by the patient themselves.

In general, dacomitinib was originally developed by Pfizer of the United States and is a targeted drug that represents the second generationEGFR-TKI technology level. Its global launch is advancing rapidly, and its indications cover EGFR mutated non-small cell lung cancer patient groups in many countries. The development background of this drug reflects the continuous efforts of global pharmaceutical companies in overcoming targeted drug resistance and improving clinical effects. It also provides more diversified options for precision treatment of lung cancer.

Reference: https://go.drugbank.com/drugs/